A systematic review of 439 studies reveals high-quality evidence supporting biologic therapies and defined treatment targets for systemic lupus erythematosus, with anifrolumab and belimumab showing superior efficacy to standard care in extrarenal disease.
A recent study compares collagenase injections with limited fasciectomy for Dupuytren’s contracture, revealing insights into recurrence rates and patient outcomes.
A study of over 3.5 million adults found that individuals with age-related macular degeneration had an 11% higher risk of developing rheumatoid arthritis, suggesting a potential link between eye and joint health.
EULAR's latest recommendations for systemic sclerosis treatment include 22 evidence-based guidelines across 8 clinical domains, marking a significant expansion from the 16 recommendations in 2017.
Despite advances in disease-modifying therapies, up to 40% of rheumatoid arthritis patients experience persistent pain, challenging traditional views of RA pathophysiology and highlighting the need for novel pain management strategies.
Conexiant
Daily News
Stay up to date with the latest clinical headlines.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Three of the fatalities showed a common pattern of symptoms and the deaths happened close to the time of dosing, while a non-fatal adverse event showed a similar proximity to dosing.
Low-dose aspirin and/or heparin treatment significantly increased live birth rates to 87.2% in women with recurrent pregnancy loss and anti-β2-glycoprotein I/HLA-DR antibodies, compared to 50.0% without treatment.
Biogen and UCB's experimental lupus treatment shows promising results in reducing disease activity for lupus patients, offering hope for new therapeutic alternatives in the field.